ST. PAUL, Minn., Feb. 14, 2017 /PRNewswire-USNewswire/ -- St. Teresa Medical, Inc, a company developing and soon to be
The award will be presented April 26 by the Federal Laboratory Consortium (FLC) for work by Dr. Stephen Rothwell, Professor of Anatomy, Physiology and Genetics at The USU's F. Edward Hébert School of Medicine and his colleagues for the licensing of SURGICLOT®, a dissolvable dressing that leaves behind the essential human clotting proteins, fibrinogen and thrombin, at the injury site. Dr. Rothwell is a co-inventor of the formulation and manufacturing technique for the production of the hemostatic bandages. He and other researchers at USU under a Cooperative Research and Development Agreement with St. Teresa Medical, performed the initial swine pre-clinical work and published the results in The Journal of Trauma-Injury Infection & Critical Care.
St. Teresa Medical exclusively licensed the technology from HJF and Virginia Commonwealth University (VCU) in 2010. "We offer our congratulations to the teams at HJF and USU and are grateful for our ongoing affiliations with these esteemed organizations," says Philip A. Messina, President and Chief Executive Officer of St. Teresa Medical, Inc.
About St. Teresa Medical, Inc.®
St. Teresa Medical, Inc. has developed a platform technology called FASTCLOT®. SURGICLOT, the technology's product used in human clinical trials, is comprised of USP grade electrospun dextran and human plasma proteins. Dextran is a branched-chain polysaccharide that has been used in medicine for many decades. It is highly soluble in liquid such as blood. Due to its high molecular weight, it is an excellent osmotic agent. SURGICLOT is the only dissolvable hemostatic agent that does not swell in the body making it ideal for cancellous bone bleeding. SURGICLOT performed well in human trials in the UK, Norway and India. (See St. Teresa Medical's website for more information at www.stteresamedical.com) The company is in the process of submitting its dossier for CE Mark for commercialization in the EU. The electrospun dextran dressing is the ideal carrier for the FASTCLOT platform technology and for clotting proteins because it is safe, dissolves rapidly and does not leave a trace. FASTCLOT® is a platform nanotechnology that will have many applications.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/st-teresa-medical-inc-technology-collaborator-to-be-presented-with-2017-award-for-excellence-in-technology-transfer-300406919.html
SOURCE St. Teresa Medical, Inc.
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All